In Brief: Cambridge NeuroScience
Cambridge NeuroScience: Grosses $9.6 mil. from directed public offering. The Cambridge, Mass. company announced closing of the sale of 1.2 mil. shares at $8 per share Nov. 22. The sale was made through Robertson, Stephens & Co. Net proceeds from the offering will be used to fund preclinical and clinical trials and general corporate purposes, CNS says...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth